Gilead expands operations in Cork, Ireland
pharmafile | May 21, 2018 | News story | Manufacturing and Production, Sales and Marketing | Gilead, Ireland, biotech, drugs, pharma, pharmaceutical
Gilead has unveiled the expansion of its Cork manufacturing site, involved in the creation of its treatments for HIV and hepatitis.
The €9.5 million quality control lab facility has been opened to accommodate the biotech’s growing presence in Ireland, after it invested close to €200 million to build a manufacturing infrastructure that now employs more than 500 people. It’s a rapid scale-up, considering Gilead established a presence in Ireland less than two decades ago.
“We are delighted to launch this significant expansion, which will have a positive impact on the production of vital medicines for hundreds of thousands of patients around the world,” said David Cadogan, Vice President of Manufacturing Operations at Gilead. “During the last five years, manufacturing of 11 Gilead products has been transferred to the Carrigtwohill plant, resulting in a significant increase in quality control testing requirements.”
The site will be used as part of the production process to manufacture medicine for distribution across Europe, the Middle East and Asia.
The overall facility already produces a quarter of Gilead’s drugs that are delivered via tablets and, as mentioned by Cadogan, 11 products in total are now manufactured at this location. There are currently 390 individuals working at the Carrigtwohill facility.
Gilead is currently in the process of expanding its manufacturing presence across the world, with news only just breaking last week that it had sought out new facilities in Europe and the US.
This move related to the biotech’s pivot towards gene therapy, particularly after its acquisition of Kite.
Ben Hargreaves
Related Content
Astellas plans to invest over €330m in new facility in Ireland
Astellas Pharma has announced that it is preparing to submit a planning application to build …
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
